What's your point? The cancer market is always going to be competitive and it won't be any difference even with CF33 and Azer-Cel. If IMU manage to capture only 10% of Cholangiocarcinoma and DLBCL in just the US then the revenue will be $100M and that's using a conservative treatment cost for current available treatment. However, the worth of both assets are expansion to other cancer treatment.
So, you are more qualified than LC but haven't previously held a high position in a multi billion biotech company???? Yet, you decided to contact her directly about question of the clinical trial for HER-Vaxx but not JT????
IMU Price at posting:
4.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)